Interferon Beta-1a

Interferons are naturally occurring proteins that are classified into three major classes - alpha, beta, and gamma. Interferon alpha, beta and gamma have overlapping yet different biologic activities. Two therapeutic forms of interferon beta are available - interferon beta-1a, produced in mammalian cells, and interferon-beta-1b, produced in bacterial expression systems Interferon beta-1a is a glycoprotein of 166 amino acids. It has 3 cysteines at positions 17, 31 and 141, a single disulfide bridge and an N-linked carbohydrate moiety primarily of the biantennary complex type attached to asparagine (Asn)-80. Interferon beta- 1a has a molecular weight of approximately 22500 Da, identical to the natural human interferon beta, and is produced by recombinant deoxyribonucleic acid (DNA) technology. Interferon beta is a cytokine with antiviral and immunomodulating activities. Interferon beta-1a is a form of recombinant human interferon used to slow disease progression and treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Interferon Beta-1a

CAS Registry Number:
Trade names:
Avonex®, Rebif®
$679 USD


Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

  • The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
  • A listing of all cited references utilized in the derivation of the OEL and ADE
  • An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

  • Fully documented. Over 20 pages in length, with calculations and cited references.
  • Save time! Unsurpassed delivery with instant download.
  • Save money. Similar documents cost 5-12 times as much.
  • Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Interferon Beta-1a, just click the ADD TO CART button.


If you're wondering about HBEL, we have something for you.

Search OEL Fastrac

Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.

Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.
  • K. Rosenthal
  • Director of Manufacturing